基于两个队列研究，标记物Ki-67是前列腺癌诊断和预后的潜在生物标志物。
Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts.
作者信息
Song Zhen, Zhou Qi, Zhang Jiang-Lei, Ouyang Jun, Zhang Zhi-Yu
机构信息
Department of Urology, Taixing People's Hospital, Taizhou 225400, Jiangsu Province, China.
Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China.
出版信息
World J Clin Cases. 2024 Jan 6;12(1):32-41. doi: 10.12998/wjcc.v12.i1.32.
BACKGROUND
Prostate cancer (PCa) is a widespread malignancy, predominantly affecting elderly males, and current methods for diagnosis and treatment of this disease continue to fall short. The marker Ki-67 (MKI67) has been previously demonstrated to correlate with the proliferation and metastasis of various cancer cells, including those of PCa. Hence, verifying the association between MKI67 and the diagnosis and prognosis of PCa, using bioinformatics databases and clinical data analysis, carries significant clinical implications.
AIM
To explore the diagnostic and prognostic efficacy of antigens identified by MKI67 expression in PCa.
METHODS
For cohort 1, the efficacy of MKI67 diagnosis was evaluated using data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases. For cohort 2, the diagnostic and prognostic power of MKI67 expression was further validated using data from 271 patients with clinical PCa.
RESULTS
In cohort 1, MKI67 expression was correlated with prostate-specific antigen (PSA), Gleason Score, T stage, and N stage. The receiver operating characteristic (ROC) curve showed a strong diagnostic ability, and the Kaplan-Meier method demonstrated that MKI67 expression was negatively associated with the progression-free interval (PFI). The time-ROC curve displayed a weak prognostic capability for MKI67 expression in PCa. In cohort 2, MKI67 expression was significantly related to the Gleason Score, T stage, and N stage; however, it was negatively associated with the PFI. The time-ROC curve revealed the stronger prognostic capability of MKI67 in patients with PCa. Multivariate COX regression analysis was performed to select risk factors, including PSA level, N stage, and MKI67 expression. A nomogram was established to predict the 3-year PFI.
CONCLUSION
MKI67 expression was positively associated with the Gleason Score, T stage, and N stage and showed a strong diagnostic and prognostic ability in PCa.
背景
前列腺癌（PCa）是一种广泛存在的恶性肿瘤，主要影响老年男性，目前该疾病的诊断和治疗方法仍存在不足。此前已证明标志物Ki-67（MKI67）与包括PCa癌细胞在内的各种癌细胞的增殖和转移相关。因此，利用生物信息学数据库和临床数据分析来验证MKI67与PCa诊断及预后之间的关联具有重要的临床意义。
目的
探讨MKI67表达所识别的抗原在PCa中的诊断和预后效能。
方法
对于队列1，使用来自癌症基因组图谱（TCGA）和基因型-组织表达（GTEx）数据库的数据评估MKI67诊断的效能。对于队列2，使用271例临床PCa患者的数据进一步验证MKI67表达的诊断和预后能力。
结果
在队列1中，MKI67表达与前列腺特异性抗原（PSA）、 Gleason评分、T分期和N分期相关。受试者工作特征（ROC）曲线显示出较强的诊断能力，Kaplan-Meier法表明MKI67表达与无进展生存期（PFI）呈负相关。时间-ROC曲线显示MKI67表达在PCa中的预后能力较弱。在队列2中，MKI67表达与Gleason评分、T分期和N分期显著相关；然而，它与PFI呈负相关。时间-ROC曲线显示MKI67在PCa患者中具有更强的预后能力。进行多变量COX回归分析以选择危险因素，包括PSA水平、N分期和MKI67表达。建立了一个列线图来预测3年PFI。
结论
MKI67表达与Gleason评分、T分期和N分期呈正相关，并且在PCa中显示出较强的诊断和预后能力。
Zotero 插件